235 related articles for article (PubMed ID: 31905298)
1. Is precision medicine possible in rheumatic diseases? Lessons from selective use of targeted therapies in patients with psoriatic arthritis.
Miyagawa I; Tanaka Y
Expert Rev Clin Immunol; 2020 Feb; 16(2):199-206. PubMed ID: 31905298
[No Abstract] [Full Text] [Related]
2. The approach to precision medicine for the treatment of psoriatic arthritis.
Miyagawa I; Tanaka Y
Immunol Med; 2020 Sep; 43(3):98-102. PubMed ID: 32306849
[TBL] [Abstract][Full Text] [Related]
3. Optimal Biologic Selection for Treatment of Psoriatic Arthritis: the Approach to Precision Medicine.
Miyagawa I; Nakayamada S; Tanaka Y
Curr Rheumatol Rep; 2019 Mar; 21(5):21. PubMed ID: 30891646
[TBL] [Abstract][Full Text] [Related]
4. Precision medicine using different biological DMARDs based on characteristic phenotypes of peripheral T helper cells in psoriatic arthritis.
Miyagawa I; Nakayamada S; Nakano K; Kubo S; Iwata S; Miyazaki Y; Yoshikawa M; Yoshinari H; Tanaka Y
Rheumatology (Oxford); 2019 Feb; 58(2):336-344. PubMed ID: 29618121
[TBL] [Abstract][Full Text] [Related]
5. The road to personalised medicine in psoriatic arthritis.
White JPE; Coates LC
Expert Rev Clin Immunol; 2021 Aug; 17(8):799-802. PubMed ID: 34000952
[No Abstract] [Full Text] [Related]
6. Tailored first-line biologic therapy in patients with rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis.
Cantini F; Niccoli L; Nannini C; Cassarà E; Kaloudi O; Giulio Favalli E; Becciolini A; Biggioggero M; Benucci M; Li Gobbi F; Grossi V; Infantino M; Meacci F; Manfredi M; Guiducci S; Bellando-Randone S; Matucci-Cerinic M; Foti R; Di Gangi M; Mosca M; Tani C; Palmieri F; Goletti D;
Semin Arthritis Rheum; 2016 Apr; 45(5):519-32. PubMed ID: 26607440
[TBL] [Abstract][Full Text] [Related]
7. Treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs: British Society for Rheumatology guideline scope.
Tillett W; Allen A; Tucker L; Chandler D; Ciurtin C; Davis C; Dick A; Foulkes A; Gullick N; Helliwell P; Jadon D; Jones G; Kyle S; Madhok V; McHugh N; Parkinson A; Raine T; Siebert S; Smith C; Coates LC
Rheumatology (Oxford); 2021 Apr; 60(4):1588-1592. PubMed ID: 33097948
[TBL] [Abstract][Full Text] [Related]
8. Lymphocyte phenotype and its application to precision medicine in systemic autoimmune diseases
Tanaka Y; Kubo S; Miyagawa I; Iwata S; Nakayamada S
Semin Arthritis Rheum; 2019 Jun; 48(6):1146-1150. PubMed ID: 31079846
[TBL] [Abstract][Full Text] [Related]
9. Optimising psoriatic arthritis therapy with immunological methods to increase standard evaluation: the protocol of an open-label multicentre, parallel-group, two-arm randomised controlled study evaluation precision medicine approach in the treatment of psoriatic arthritis.
Ooms A; Al-Mossawi H; Bennett L; Bogale M; Bowness P; Francis A; Goodyear C; Kirkham BW; Lalnunhlimi S; McInnes IB; Richards D; Siebert S; Taams LS; Tulunay Virlan A; Yager N; Coates LC
BMJ Open; 2023 Sep; 13(9):e078539. PubMed ID: 37770264
[TBL] [Abstract][Full Text] [Related]
10. Treatment strategies for psoriatic arthritis.
Schemoul J; Poulain C; Claudepierre P
Joint Bone Spine; 2018 Oct; 85(5):537-544. PubMed ID: 29155104
[TBL] [Abstract][Full Text] [Related]
11. Novel Therapeutics in Psoriatic Arthritis. What Is in the Pipeline?
Elalouf O; Chandran V
Curr Rheumatol Rep; 2018 May; 20(7):36. PubMed ID: 29846825
[TBL] [Abstract][Full Text] [Related]
12. Impact of biologic DMARDs on quality of life: 12-month results of a rheumatic diseases cohort using the Brazilian EQ-5D tariff.
Alves de Oliveira Junior H; Pereira da Veiga T; Acurcio FA; Almeida AM; Ribeiro Dos Santos JB; da Silva MRR; Kakehasi AM; Cherchiglia ML
Hosp Pract (1995); 2020 Oct; 48(4):213-222. PubMed ID: 32567403
[TBL] [Abstract][Full Text] [Related]
13. Infection risk in patients undergoing treatment for inflammatory arthritis: non-biologics versus biologics.
Chiu YM; Chen DY
Expert Rev Clin Immunol; 2020 Feb; 16(2):207-228. PubMed ID: 31852268
[No Abstract] [Full Text] [Related]
14. Singapore Chapter of Rheumatologists consensus statement on the eligibility for government subsidy of biologic disease modifying anti-rheumatic agents for the treatment of psoriatic arthritis.
Lahiri M; Teng GG; Cheung PP; Suresh E; Chia FL; Lui NL; Koh DR; Koh WH; Leong KP; Lim AYN; Ng SC; Thumboo J; Lau TC; Leong KH
Int J Rheum Dis; 2017 Oct; 20(10):1527-1540. PubMed ID: 26353916
[TBL] [Abstract][Full Text] [Related]
15. 2017 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty.
Goodman SM; Springer B; Guyatt G; Abdel MP; Dasa V; George M; Gewurz-Singer O; Giles JT; Johnson B; Lee S; Mandl LA; Mont MA; Sculco P; Sporer S; Stryker L; Turgunbaev M; Brause B; Chen AF; Gililland J; Goodman M; Hurley-Rosenblatt A; Kirou K; Losina E; MacKenzie R; Michaud K; Mikuls T; Russell L; Sah A; Miller AS; Singh JA; Yates A
Arthritis Rheumatol; 2017 Aug; 69(8):1538-1551. PubMed ID: 28620948
[TBL] [Abstract][Full Text] [Related]
16. First-time prescriptions of biological disease-modifying antirheumatic drugs in rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis 2002-2011: data from the NOR-DMARD register.
Lie E; Fagerli KM; Mikkelsen K; Rødevand E; Lexberg A; Kalstad S; Uhlig T; Kvien TK
Ann Rheum Dis; 2014 Oct; 73(10):1905-6. PubMed ID: 24989896
[No Abstract] [Full Text] [Related]
17. Evaluating upadacitinib for the treatment of psoriatic arthritis.
Akpabio A; Adebajo A
Expert Opin Pharmacother; 2022 Feb; 23(2):169-173. PubMed ID: 35014922
[TBL] [Abstract][Full Text] [Related]
18. Psoriatic arthritis: current therapy and future approaches.
Huynh D; Kavanaugh A
Rheumatology (Oxford); 2015 Jan; 54(1):20-8. PubMed ID: 25125588
[TBL] [Abstract][Full Text] [Related]
19. Second-line biologic therapy optimization in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
Cantini F; Niccoli L; Nannini C; Cassarà E; Kaloudi O; Giulio Favalli E; Becciolini A; Benucci M; Gobbi FL; Guiducci S; Foti R; Mosca M; Goletti D
Semin Arthritis Rheum; 2017 Oct; 47(2):183-192. PubMed ID: 28413099
[TBL] [Abstract][Full Text] [Related]
20. The 2022 British Society for Rheumatology guideline for the treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs.
Tucker L; Allen A; Chandler D; Ciurtin C; Dick A; Foulkes A; Gullick N; Helliwell P; Jadon D; Jones G; Kyle S; Madhok V; McHugh N; Parkinson A; Raine T; Siebert S; Smith C; Tillett W; Coates LC
Rheumatology (Oxford); 2022 Aug; 61(9):e255-e266. PubMed ID: 35640657
[No Abstract] [Full Text] [Related]
[Next] [New Search]
